Pharming Group N.V. (ENXTAM:PHARM) is looking acquisitions. During the company?s first half 2023 results call, Jeroen Wakkerman, Chief Financial Officer said that ?We continue to look at investments on acquisitions and in-licensing of mid- to late-stage opportunities in rare diseases to build the company further?.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.873 EUR | -0.68% | -0.40% | -15.32% |
05-08 | Pharming Group N.V. Provides Revenue Guidance for 2024 | CI |
05-08 | Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.32% | 636M | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |
- Stock Market
- Equities
- PHARM Stock
- News Pharming Group N.V.
- Pharming Seeks Acquisitions